Advertisement

Timing and Typology of Cardio-Embolic Prevention in Patients with Atrial Fibrillation

  • G. Di Pasquale
  • G. Casella
  • P.C. Pavesi
Conference paper

Conclusions

OAT currently represents the most effective therapy for cardio-embolic prevention in patients with non-valvular AF at moderate-to-high risk. Antiplatelet therapy may represent an alternative for low-risk patients or patients who are poor candidates for OAT, due to a high risk of bleeding or limited compliance. The hope for the future is the development of newer alternatives to OAT with a more convenient pharmacological profile, less risk of bleeding and easier management [21]. At present, oral direct thrombin inhibitors seem the most promising alternatives, but further studies are needed to confirm their safety.

Keywords

Atrial Fibrillation International Normalise Ratio Stroke Prevention Atrial Fibrillation Patient Left Atrial Appendage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Go AS, Hylek EM, Phillips KA et al (2001) Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 285:2370–2375PubMedCrossRefGoogle Scholar
  2. 2.
    Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 22:983–988PubMedGoogle Scholar
  3. 3.
    Singer DE, Albers GW, Dalen JE et al (2004) Antithrombotic therapy in atrial fibrillation. The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 126: S429–S456CrossRefGoogle Scholar
  4. 4.
    Hart RG, Benavente O, McBride R et al (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131:492–501PubMedGoogle Scholar
  5. 5.
    Fuster V, Rydén LE, Asinger RW et al (2001) ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 22:1852–1923PubMedCrossRefGoogle Scholar
  6. 6.
    Di Pasquale G, Cerè E, Lombardi A et al (2003) Anticoagulation therapy of atrial fibrillation in the elderly. In: Gulizia M (Ed) New advances in heart failure and atrial fibrillation. Springer, Milan, pp 329–334Google Scholar
  7. 7.
    Palareti G, Leali N, Coccheri S et al (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 348:423–428PubMedCrossRefGoogle Scholar
  8. 8.
    Wehinger C, Stollberger C, Langer T et al (2001) Evaluation of risk factors for stroke/embolism and of complications due to anticolagulant therapy in atrial fibrillation. Stroke 32:2246–2252PubMedGoogle Scholar
  9. 9.
    Ansell J, Hirsh J, Dalen J et al (2001) Managing oral anticoagulant therapy. Chest 119(Suppl):S22–S38CrossRefGoogle Scholar
  10. 10.
    Chiquette E, Amato MG, Bussey HI (1998) Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patients outcome and health care costs. Arch Intern Med 158:1641–1647PubMedCrossRefGoogle Scholar
  11. 11.
    Weitz JI, Hirsh J, Samama MM (2004) New anticoagulant drugs. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:S265–S286CrossRefGoogle Scholar
  12. 12.
    Eriksson UG, Bredberg U, Gislén K et al (2003) Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 59:35–43PubMedGoogle Scholar
  13. 13.
    Executive Steering Committee on behalf of the SPORTIF III investigators (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691–1698CrossRefGoogle Scholar
  14. 14.
    SPORTIF Executive Steering Committee for the SPORTIF V Investigators (2005) Ximelagatran vs warfarin for stroke prevention in patients with non valvular atrial fibrillation: a randomized trial. JAMA, 293:690–698CrossRefGoogle Scholar
  15. 15.
    Diener HC (2004) SPORTIF-III/V combined analysis. Cerebrovasc Dis 17(Suppl.5):16Google Scholar
  16. 16.
    Sievert H, Lesh MD, Trepels T et al (2002) Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation. Early clinical experience. Circulation 105:1887–1889PubMedCrossRefGoogle Scholar
  17. 17.
    Barbato G, Carinci V, Pergolini F et al (2005) Percutaneous occlusion of the left appendage for systemic embolism prevention in patients with atrial fibrillation: state of the art and report of two cases. Ital Heart J (submitted)Google Scholar
  18. 18.
    The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833CrossRefGoogle Scholar
  19. 19.
    Van Gelder IC, Hagens VE, Bosker HA et al (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. N Engl J Med 347:1834–1840PubMedCrossRefGoogle Scholar
  20. 20.
    Wyse DG (2004) Personal communicationGoogle Scholar
  21. 21.
    Di Pasquale G, Casella G (2005) Antithrombotic strategies for atrial fibrillation: on the threshhold for a change? Yes. J Thromb Haemost (in press)Google Scholar

Copyright information

© Springer-Verlag Italia 2005

Authors and Affiliations

  • G. Di Pasquale
    • 1
  • G. Casella
    • 1
  • P.C. Pavesi
    • 1
  1. 1.Division of CardiologyMaggiore HospitalBolognaItaly

Personalised recommendations